HC Wainwright & Co. Reiterates Buy on Werewolf Therapeutics, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andres Maldonado has reiterated a Buy rating on Werewolf Therapeutics (NASDAQ:HOWL) and maintained a $15 price target on the stock.
November 15, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Andres Maldonado has reiterated a Buy rating on Werewolf Therapeutics and maintained a $15 price target.
The reiteration of a Buy rating and the maintenance of a $15 price target by a reputable analyst could lead to increased investor confidence and a potential short-term positive impact on HOWL's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100